CN104039816B - 包含重组毒素的针对艰难梭菌的疫苗 - Google Patents

包含重组毒素的针对艰难梭菌的疫苗 Download PDF

Info

Publication number
CN104039816B
CN104039816B CN201380005667.4A CN201380005667A CN104039816B CN 104039816 B CN104039816 B CN 104039816B CN 201380005667 A CN201380005667 A CN 201380005667A CN 104039816 B CN104039816 B CN 104039816B
Authority
CN
China
Prior art keywords
seq
cdta
tcda
tcdb
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380005667.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104039816A (zh
Inventor
J.H.海恩里希斯
J-L.博默
S.L.塞科尔
A.R.格尔克
I.卡罗亚圭拉
M-P.金泰尔
M.S.霍尔顿
M.R.米翟夫斯基
J.M.斯金纳
P.J.A.森德梅耶
S.苏布拉马尼安
K.H.A.v.d.海登利夫肯斯
S.王
J.谢
R.F.埃克索科诺斯特尔
J.K.佐尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Merck Sharp and Dohme LLC
Original Assignee
Intervet International BV
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV, Schering Corp filed Critical Intervet International BV
Publication of CN104039816A publication Critical patent/CN104039816A/zh
Application granted granted Critical
Publication of CN104039816B publication Critical patent/CN104039816B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380005667.4A 2012-01-27 2013-01-25 包含重组毒素的针对艰难梭菌的疫苗 Expired - Fee Related CN104039816B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261591631P 2012-01-27 2012-01-27
US61/591631 2012-01-27
US61/591,631 2012-01-27
US201261596419P 2012-02-08 2012-02-08
US61/596,419 2012-02-08
US61/596419 2012-02-08
US201261703754P 2012-09-20 2012-09-20
US61/703,754 2012-09-20
US61/703754 2012-09-20
PCT/US2013/023189 WO2013112867A1 (en) 2012-01-27 2013-01-25 Vaccines against clostridium difficile comprising recombinant toxins

Publications (2)

Publication Number Publication Date
CN104039816A CN104039816A (zh) 2014-09-10
CN104039816B true CN104039816B (zh) 2018-02-09

Family

ID=48873956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380005667.4A Expired - Fee Related CN104039816B (zh) 2012-01-27 2013-01-25 包含重组毒素的针对艰难梭菌的疫苗

Country Status (14)

Country Link
US (1) US9388394B2 (enExample)
EP (1) EP2807186A4 (enExample)
JP (2) JP2015506948A (enExample)
KR (1) KR20140117433A (enExample)
CN (1) CN104039816B (enExample)
AR (1) AR089797A1 (enExample)
AU (1) AU2013211973B2 (enExample)
BR (1) BR112014018432A8 (enExample)
CA (1) CA2856443A1 (enExample)
IN (1) IN2014CN04187A (enExample)
MX (1) MX351074B (enExample)
RU (1) RU2014134365A (enExample)
TW (1) TW201335178A (enExample)
WO (1) WO2013112867A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391236B (es) 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
SG11201402375VA (en) * 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
CA2910200A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
SI3160500T1 (sl) * 2014-06-25 2019-11-29 Glaxosmithkline Biologicals Sa Imunogeni sestavek proti Clostridium difficile
JP2017212882A (ja) * 2014-10-10 2017-12-07 学校法人 名城大学 アセチルエステラーゼ及びその利用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112017024443A2 (pt) 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
ES2893838T3 (es) 2016-03-02 2022-02-10 Merz Pharma Gmbh & Co Kgaa Composición que comprende toxina botulínica
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2017375590A1 (en) * 2016-12-14 2019-06-13 Beijing Genomics Institute At Shenzhen Human genetic markers associated with response to treatments that target Clostridium difficile toxin B
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
AU2018236352B2 (en) * 2017-03-15 2024-04-04 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
JP7349366B2 (ja) * 2017-06-09 2023-09-22 ヒプラ シエンティフィック エセ．エレ．ウ． クロストリジウム類毒素を含むワクチン
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
TW202035437A (zh) * 2018-10-17 2020-10-01 陳啟彰 預防艱難梭菌（clostridium difficile）感染的免疫原性組合物及方法
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途
JP2023134918A (ja) * 2022-03-15 2023-09-28 株式会社荏原製作所 研磨方法および研磨装置
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093801A1 (en) * 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of campylobacter jejuni

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
EP1699814A4 (en) 2003-12-08 2009-01-14 Hybridon Inc MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF COMPOUNDS FORMED FROM SMALL OLIGONUCLEOTIDES
DK1766093T3 (da) 2004-02-06 2011-10-03 Univ Massachusetts Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US20070243199A1 (en) * 2006-03-30 2007-10-18 Embrex, Inc. Methods and compositions for vaccination of poultry
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
US8420352B2 (en) 2009-08-27 2013-04-16 Synaptic Research, Llc Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
EP2519257A4 (en) * 2009-12-02 2014-10-15 Univ Tufts ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
EP3167899B1 (en) 2010-09-03 2021-03-24 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
MX391236B (es) * 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093801A1 (en) * 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of campylobacter jejuni

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STRUCTURAL STUDIES ON ACTIN­ADP RIBOSYLATING BINARY TOXIN FROM C. DIFFICILE;AMIT SUNDRIYAL;《A thesis submitted for the degree of Doctor of Philosophy University of Bath Department of Biology and Biochemistry》;20100228;摘要，正文第40、158-161页 *

Also Published As

Publication number Publication date
AR089797A1 (es) 2014-09-17
JP2017141226A (ja) 2017-08-17
BR112014018432A8 (pt) 2017-07-11
US9388394B2 (en) 2016-07-12
WO2013112867A1 (en) 2013-08-01
MX351074B (es) 2017-09-28
MX2014009106A (es) 2014-11-10
IN2014CN04187A (enExample) 2015-07-17
AU2013211973A1 (en) 2014-06-12
JP2015506948A (ja) 2015-03-05
AU2013211973B2 (en) 2017-10-12
TW201335178A (zh) 2013-09-01
EP2807186A1 (en) 2014-12-03
CA2856443A1 (en) 2013-08-01
KR20140117433A (ko) 2014-10-07
RU2014134365A (ru) 2016-03-20
CN104039816A (zh) 2014-09-10
US20150044250A1 (en) 2015-02-12
BR112014018432A2 (enExample) 2017-06-20
EP2807186A4 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
CN104039816B (zh) 包含重组毒素的针对艰难梭菌的疫苗
US12324831B2 (en) Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
CN111479821B (zh) 作为疫苗的修饰的梭菌神经毒素和结合疫苗平台
KR20140101835A (ko) 클로스트리듐 디피실레 톡신-기반 백신
TWI605056B (zh) 用於治療艱難梭狀芽孢桿菌（Clostridium difficile）相關疾病之組成物及方法
US20200123210A1 (en) Immunogenic preparations and methods against clostridium difficile infection
HK1197887B (en) Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
HK1197887A (en) Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180209

Termination date: 20190125